AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 12/17/25

2025-12-17 23:01:04 ET The Thesis: A Bullish Case Betting on the Future Pipeline Addressing Many Conditions Read the full article on Seeking Alpha For further details see: Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

2025-12-10 12:56:53 ET More on Teva Pharmaceutical, Amneal Pharmaceuticals Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare...

Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) toda...

Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapies CREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each dose Findings highlight C...

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences: Piper Sandler 2025...

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s albuterol sulfate inhalation aerosol (90 mcg ...

Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company...

2025-11-13 16:45:58 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That...

BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s iohexol injection (300 mg Iodine/mL), the first ge...

2025-11-05 11:00:24 ET Shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) traded at a new 52-week high today and are currently trading at $11.41. So far today, approximately 396.74k shares have been exchanged, as compared to an average 30-day volume of 1.5M shares. Amneal Pharmac...